Nastorazepide (Z-360)
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206018

CAS#: 209219-38-5

Description: Nastorazepide, also known as Z-360, is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells.


Chemical Structure

img
Nastorazepide (Z-360)
CAS# 209219-38-5

Theoretical Analysis

MedKoo Cat#: 206018
Name: Nastorazepide (Z-360)
CAS#: 209219-38-5
Chemical Formula: C29H36N4O5
Exact Mass: 520.27
Molecular Weight: 520.620
Elemental Analysis: C, 66.90; H, 6.97; N, 10.76; O, 15.37

Price and Availability

Size Price Availability Quantity
5mg USD 150 Ready to ship
10mg USD 250 Ready to ship
25mg USD 450 Ready to ship
50mg USD 750 Ready to ship
100mg USD 1250 Ready to ship
200mg USD 2050 Ready to Ship
500mg USD 3650 Ready to Ship
1g USD 4950 Ready to Ship
Bulk inquiry

Synonym: Z360; Z-360; Z 360; Nastorazepide.

IUPAC/Chemical Name: (R)-3-(3-(5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)ureido)benzoic acid

InChi Key: VIJCCFFEBCOOIE-JOCHJYFZSA-N

InChi Code: InChI=1S/C29H36N4O5/c1-29(2,3)25(34)18-33-24-15-8-7-14-23(24)32(21-12-5-4-6-13-21)17-22(26(33)35)31-28(38)30-20-11-9-10-19(16-20)27(36)37/h7-11,14-16,21-22H,4-6,12-13,17-18H2,1-3H3,(H,36,37)(H2,30,31,38)/t22-/m1/s1

SMILES Code: O=C(O)C1=CC=CC(NC(N[C@@H]2CN(C3CCCCC3)C4=CC=CC=C4N(CC(C(C)(C)C)=O)C2=O)=O)=C1

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:         

Biological target: Nastorazepide (Z-360) is a selective 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist.
In vitro activity: To determine the antagonistic effect of Z-360 on the CCK-2 receptor, the intracellular Ca2+ release was measured. Whereas 1 nmol/l CCK-8 increased intracellular Ca2+ release by CHO-K1/CCK-2 cells, pretreatment with Z-360F (10−11 to 10−5 mol/l) inhibited CCK-8-induced intracellular Ca2+ release in a concentration-dependent manner (IC50 value: 11 nmol/l, Fig. 3). However, Z-360F at 10−5 mol/l showed no effect on Ca2+ release in CHO-K1/CCK-2 cells without CCK-8 stimulation. As the degree of the Ca2+ release from unstimulated CHO-K1/CCK-2 cells is similar to untransfected cells (intact CHO-K1 cells), we defined as basal activity using unstimulated CHO-K1/CCK-2 cells. As Z-360F alone did not increased calcium release in CHO-K1/CCK-2 cells comparing to basal activity, it was considered that Z-360 did not act as agonist activity for classical CCK-2 receptor, at least at range of 10−5 M from 10−11 M. These results demonstrated that Z-360 shows selective antagonistic activity for the human CCK-2 receptor without an agonistic activity for CCK-2 receptor. Reference: Cancer Chemother Pharmacol. 2008 Apr;61(5):883-92. https://dx.doi.org/10.1007/s00280-007-0591-8
In vivo activity: MiaPaCa2 cells were injected subcutaneously into the right flanks of nude mice and allowed to establish for 14 days. Z-360 was then administered orally to the mice at doses of 10, 30, or 100 mg/kg once daily for 21 days. Z-360 significantly inhibited tumor growth as measured by both tumor size (Fig. 4a) and tumor weight (Fig. 4b) in a dose-dependent manner. As shown in Fig. 4b, administration of Z-360 at 10, 30, and 100 mg/kg resulted in 16.5, 39.6, and 41.7% inhibition of final tumor weight, respectively. This dose-dependent inhibitory activity was significant at doses of 30 mg/kg (P < 0.05) and 100 mg/kg (P < 0.01). Reference: Cancer Chemother Pharmacol. 2008 Apr;61(5):883-92. https://dx.doi.org/10.1007/s00280-007-0591-8

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 32.0 61.50

Preparing Stock Solutions

The following data is based on the product molecular weight 520.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol: 1. Kawasaki D, Emori Y, Eta R, Iino Y, Hamano H, Yoshinaga K, Tanaka T, Takei M, Watson SA. Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro. Cancer Chemother Pharmacol. 2008 Apr;61(5):883-92. doi: 10.1007/s00280-007-0591-8. Epub 2007 Sep 28. PMID: 17901954.
In vivo protocol: 1. Kawasaki D, Emori Y, Eta R, Iino Y, Hamano H, Yoshinaga K, Tanaka T, Takei M, Watson SA. Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro. Cancer Chemother Pharmacol. 2008 Apr;61(5):883-92. doi: 10.1007/s00280-007-0591-8. Epub 2007 Sep 28. PMID: 17901954. 2. Orikawa Y, Kato H, Seto K, Kobayashi N, Yoshinaga K, Hamano H, Hori Y, Meyer T, Takei M. Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice. Mol Pain. 2010 Oct 28;6:72. doi: 10.1186/1744-8069-6-72. PMID: 20979661; PMCID: PMC2987997.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kato H, Seto K, Kobayashi N, Yoshinaga K, Meyer T, Takei M. CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells. Life Sci. 2011 Oct 24;89(17-18):603-8. doi: 10.1016/j.lfs.2011.07.019. Epub 2011 Aug 3. PubMed PMID: 21839751.

(Last Update: 4/20/2016)